NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties
The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement...
Nationally negotiated drugs
NHSA Completes 2022 NRDL Update with 111 New Listings, Focus on COVID-19 Treatments
The National Healthcare Security Administration (NHSA) held a press conference to mark the completion of...
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...
NHSA Completes Expert Review for NRDL Price Negotiation Process
The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...
NHSA Launches Expert Review for 2025 NRDL Update in China
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert...
NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion
The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed...
Shandong Releases Off-Label Drug Use Consensus, Expanding Clinical Guidance
The Shandong Pharmaceutical Association (SPA) has released the “Shandong Province Expert Consensus on Off-label Drug...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...